...
| Items | Proposed improvement | Planned Release date (*this is provisional only and is subject to change) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | LOINC timeline changes - please refer to Roadmap link here LOINC | July 2018 and potentially other future releases .- On hold | |||||||
| 2 | Revision of IS A relationships for anatomy concepts The new anatomy concept model has implemented the new enhanced Description Logic features, e.g. reflective reflexive and transitive propertyproperties, general concept additional axioms, for consistent logical modeling. However, the new model cannot be implemented in production because these DL features currently are not available in production. The implementation of them will depend on the enhanced logic profile for SNOMED CT which is under development by the Modeling AG. Yet, the inferred IS A relationship The inferred IS A relationships from the OWL anatomy ontology can be have been reviewed and the changes have been implemented in the production. This will utilise the outcomes of the new anatomy model as well as evaluate the design of the new model. In particular, it is important to review the changes of IS-A relationships in anatomy for quality assurance and minimise The potential impact to other hierarchies, such as disorders, procedures, observables, situations etc are also reviewed as part of the project. The first subject area for revision is the revision of sub-hierarchy of skin structure. The majority changes have been made in the January 2018 26107004|Structure of musculoskeletal system (body structure)| has been planned for the January 2019 release. The rest body systems will be completed in July 2018 release.revised in the future releases. The For July 2018 release, the subject area for revision of IS A relationships will be determined and updated in the following confluence page. | July 2018 January 2019 International Edition | |||||||
| 3 | Summary of Drugs changes Groupers Chemical structure
Groupers Dispositions
Groupers Intended site
Medicinal product (MP)
Medicinal product form (MPF)
Clinical drug (CD)
Pharmaceuticaldose form
General The Alpha Release is a snapshot of the work-in-progress authoring environment; not all concepts are in scope for review at this time. Feedback given for concepts noted as out of scope will be rejected. For drugs:
For dose forms:
Briefing Briefing note - Use of Additional Axiom Functionality and Remodeling Product Roles.pdf (disposition, structural)
MP-containing
MP-only New concepts created (n≈3800) MPF-containing
MPF-only New concepts created (n≈2800) Clinical drug Synonyms matching FSN removed for existing concepts (n≈4900) Role:
New semantic tags, attribute and hierarchies added and MRCM change made to support National Extension Model.
Updated briefing: Briefing note - Implications of describing liquid dose form product concepts using presentation strength.pdfv2, can be found on second table of this page Reference Documentation - Drug Model | January 2019 International July 2018 International Edition | |||||||
| 4 | Summary of Substances Changes Top Level
Disposition groupers
Role groupers Role groupers within the substances hierarchy are being inactivated where this is possible without creating disruption in other hierarchies. At the start of this work there were approximately 600 role groupers. Currently in the region of 100 role grouper substance concepts have been inactivated or remodelled.This work is ongoing. Many of these role grouper concepts remain in the substances hierarchy pending a solution for the roles concepts within the terminology as a whole and so will still be present in the July 2018 release. Structural groupers Structural groupers within the substance hierarchy have been modelled as primitive concepts. Existing structural grouper concepts in the substances hierarchy have been retained where appropriate and have been remodelled to conform to SCT Editorial policy. New structural grouper concepts have been added. Groupers that identify X or derivatives where X is a specific substance will be inactivated. Some of these concepts have already been inactivated. As the implementation of the IS Modification attibute is carried out the remainder of these concepts will be inactivated. Structural groupers that reference a chemical group will be retained. e.g. Amides and derivatives (substance) Where the structural group name also refers to a specific chemical the grouper has been re-termed “Substance with X structure” e.g. Substance with tetracycline structure (substance) Combined groupers Combined groupers that include a role will be inactivated where this is possible without causing disruption in other hierarchies. Inactivation of some of these concepts in the substances hierarchy is waiting on a solution for the roles concepts within the terminology as a whole and so will still be present in the July 2018 release. Groupers of disposition + structure will be retained in the substance hierarchy. Existing concepts have been remodelled to conform to SCT Editorial policy. Examples as below. Antimony compound with antiprotozoal mechanism of action (substance) Quaternary ammonium compound with anticholinergic mechanism of action (substance) Piperidine derivative with histamine receptor antagonist mechanism of action (substance) New concepts will be added as required. Use of the Is Modification attribute The implementation of the IS Modification attibute has been started. This has achieved a flattening of the substance hierarchy. Priority has been given to the remodelling of substances associated with the medicinal products. This work is ongoing. The following guidelines have been developed. 1. Substances may have zero to many Is modification attribute(s). e.g Iodine (131-I) labelled monoclonal antibody (substance) has 2 IS MODIFICATION attribute values. 2. Salts have a IS MODIFICATION relationship to the base e.g. Doxepin hydrochloride (substance) IS MODIFICATION of Doxepin (substance) 3. Hydrates have a IS MODIFICATION relationship to the unspecified salt e.g. Caffeine hydrate (substance) IS MODIFICATION of Caffeine (substance) 4. Anhydrous salts have a IS MODIFICATION relationship to the unspecified salt e.g. Theophylline anhydrous (substance) IS MODIFICATION of Theophylline (substance) 5. Stereoisomers are subtypes of the unspecified substance. e.g.. Dextrothyroxine IS A thyroxine. 6. There is no IS MODIFICATION relationship between stereoisomers. Further guidelines will be added to the published documentation as they are developed. The initial population of the IS MODIFICATION attribute is still subject to manual authoring input to ensure compliance to Editorial guidelines and so some areas of content may appear to be non-conformant in the Alpha release data. | July 2018 International Edition | 5 | Internal QA Test and procedure status: Inactivated 143 concepts in the Situations and Findings hierarchies with pattern "Test/procedure OFFERED" and "Test/procedure NOT OFFERED" as these represent an administrative status. | 6 | Internal QA Inactivation of Agencies and organizations (qualifier value) and subtypes: moved to UK extension i.e. 66 concepts inactivated. | |||
| 7 |
| ||||||||
| January 2019 Release | ||||||||
| 5 | Remodeling of hypersensitive conditions
Hypersensitivity, allergy and pseudoallergy condition are modelled by general concept inclusion (GCI) axioms. The relationships in the GCIs are sufficient conditions which are excluded from the inferred relationships. The GCIs in the OWL axiom refset must be used with stated relationship file to enable correct classification for hypersensitivity conditions. In addition to the changes to the concept model, the FSNs and Preferred terms will be updated to ensure consistent description patterns. The changes are word order in descriptions and they do not change the meaning. For example, Amoxicillin allergy (disorder) would be changed to Allergy to amoxicillin (disorder). changes in the substance hierarchy as the result of Allergy project requirements (Allergies-30 and Allergies-32):
| ||||||||
| 6 | Summary of Organism Changes
| January 2019 Release | |||||||
| 7 | Quality improvements on Clinical Findings
| Jan 2019 International Edition | |||||||
| 8 | Replacement of OWL conversion script with a link to the open source directory In January 2017 the original OWL conversion script (a.k.a. the "Spackman OWL script") was removed from the International Edition package, and has since been published as a separate artefact alongside each Release. Because this script does not recognize the two new OWL refsets (see section 3.3.2 of these Release Notes), the Terminology Release Advisory Group has determined that the script should no longer be distributed. Going forward, Release Notes will now include a link to the new open source OWL conversion toolkit that can be found in the following repository (including documentation on its use): https://github.com/IHTSDO/snomed-owl-toolkit Please contact SNOMED International at support@snomed.org if you would like to provide any feedback on ways to extend and improve the new toolkit. | July 2018 International Edition | |||||||
| 9 | Deprecation of the Technical Guide Exemplars document from the International Edition release package The Terminology Release Advisory Group has confirmed that there should be no impact from removing this almost entirely static document from the International Edition release package, and hosting it instead in a Confluence Page. From the July 2018 International release then, we will deprecate this file (doc_Icd10MapTechnicalGuideExemplars_[date].xlsx) from the Release package, and instead provide a link in the Release Notes to the new Confluence Page. Please see section 2.4.1.3 of the Release Notes for the relevant link. | July 2018 International Edition | |||||||
| 10 | Replacement of the Stated Relationship files with the new OWL Axiom refset files Following the feedback, the normal stated relationship file will still be available in the January 2019 release package and the partial OWL axiom refset will include all description logic features that cannot be represented in the stated relationship file. The complete OWL axiom reference set, which includes all logical definitions and the enhanced DL features, will be available on request in the January 2019 release. In the July 2019 release, the stated relationship file will be replaced by the complete OWL Axiom refset file. The stated relationship file will NOT be included in the international release; however, it may still be available on request to support migration to the OWL Axiom refset.
The inferred relationship file will maintain the same format and structure, though it will no longer contain all necessary and sufficient conditions. The inferred relationship file is represented in Necessary Normal Form for distribution of relationships. It is a collection of all the necessary conditions and represents a subset of the full semantics from the 2018 July release and onwards. Most users will benefit from the improvements in the inferred relationships without requiring changes to their existing systems. A set of documentations has been developed to support the Logic Profile Enhancements.
| 8 | January 2019 International Edition |